Mind Medicine (MindMed) Inc.
MNMD
Updated: 23/09/2026, 03:43:47
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
No summaries found.
- Share price
- $20.69
- Market cap
- $1.56B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Robert Barrow
- Employees
- 74
- IPO date
- 15/11/2016
- Beta
- 2.621
- Last dividend
- $0.00
- Day range
- $19.95 – $21.10
- 52-week range
- $4.70 – $21.08
- 1-day performance
- 0.44%
- 1-year performance
- 340.21%
- Current drawdown (1Y)
- -1.85%
- CIK
- 0001813814
- CUSIP
- 60255C109
- ISIN
- CA24477V1058
- Created
- 07/12/2025, 05:18:05
- Last update
- 23/09/2026, 03:43:47
Track Mind Medicine (MindMed) Inc. with an AI analyst
See which prediction-market events move MNMD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.